MedPath

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC ...

Ivonescimab shows promising anti-tumor activity and safety in CRC, TNBC, and HNSCC, with encouraging Phase II data supporting its clinical development expansion beyond metastatic NSCLC, as presented at ESMO 2024.


Reference News

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC ...

Ivonescimab shows promising anti-tumor activity and safety in CRC, TNBC, and HNSCC, with encouraging Phase II data supporting its clinical development expansion beyond metastatic NSCLC, as presented at ESMO 2024.

© Copyright 2025. All Rights Reserved by MedPath